Consistent with our data, Lowther et al., demonstrated that the percentage of TIM-3 positivity on peripheral Tregs from glioblastoma patients was not significantly different to peripheral Tregs from grade II and III glioma patients [103]. This evidence concerns the gene HAVCR2 and central nervous system cancer.